Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareSource GA AATD Augmentation Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentCareSource Georgia MedicaidPolicy GA-MED-P-366579

    Alpha1-proteinase inhibitor augmentation therapy for severe alpha1-antitrypsin deficiency

    Customize your policy alerts

    Sign up for caresourcegeorgia Policy GA-MED-P-366579 alerts

    Get alerted when Policy GA-MED-P-366579 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for Aralast NP, Glassia, Prolastin C, and Zemaira augmentation therapy in adults with clinically evident emphysema caused by severe alpha1-antitrypsin deficiency.

    Policy Summary
    PayerCareSource Georgia Medicaid
    PolicyAlpha1-proteinase inhibitor augmentation therapy for severe alpha1-antitrypsin deficiency
    Policy CodePolicy GA-MED-P-366579
    Change TypeClinical criteria and coverage update
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for alpha1-proteinase inhibitor therapy; the benefit is medical, with pharmacy coverage allowed for Glassia.
    SourceLink
    POLICY UPDATE CHANGES

    The policy history documents removal of a lower FEV1 limit and the rate-of-decline requirement in 2023.

    The policy history documents addition of a liver-transplant exclusion in 2023.

    The policy was updated with references on March 10, 2026.

    4Covered products
    18+Minimum age
    60 mg/kg weeklyDosage limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 monthsInitial approval
    12 monthsReauthorization

    Coverage Criteria

    Initial Therapy Criteria

    Initial authorization is covered when all of the following are met.

    Initial authorization

    • Eligibility and clinical requirements

      • Member is at least 18 years of age; medication is prescribed by or in consultation with a pulmonologist; member has clinically evident emphysema due to severe alpha1-antitrypsin deficiency; member is a never-smoker or has been a non-smoker for at least 3 months; member complies with at least one prescribed supportive therapy, such as bronchodilators, pulmonary rehabilitation, or oxygen; and member has not had a liver transplant.
    • Laboratory and pulmonary findings

      • Chart notes include laboratory reports showing a pretreatment alpha1-antitrypsin serum level less than 11 micromol/L or equivalent, a high-risk genotype such as Pi*ZZ, Pi*ZNull, or Pi*NullNull, and a pretreatment FEV1 of 65% predicted or less.AAT <11 micromol/L; FEV1 ≤65% predicted

    Continuation Therapy Criteria

    Reauthorization is covered when all of the following are met.

    Continuation therapy

    • Smoking abstinence

      • Member continues to abstain from smoking.
    • Treatment response or disease monitoring

      • AAT level is at or above the protective threshold.AAT ≥11 micromol/L
      • Spirometry demonstrates a slowed rate of FEV1 decline.
      • CT densitometry demonstrates slowed progression of anatomic lung disease.

    Members who have had a liver transplant are excluded from coverage under this policy.

    Alpha1-proteinase inhibitor is not medically necessary for the treatment of conditions or indications not listed in this policy. Other indications should be directed to the applicable OffLabel policy.

    Clinical Thresholds

    Pretreatment alpha1-antitrypsin serum level
    Required pretreatment levelLess than 11 micromol/L or equivalent
    TimingPretreatment alpha1-antitrypsin serum level
    DocumentationLaboratory report must document the serum level
    Pretreatment FEV1
    Required pretreatment FEV165% predicted or less
    AssessmentPretreatment pulmonary function measurement
    DocumentationChart notes must include the pretreatment FEV1 result

    Authorization and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for alpha1-proteinase inhibitor therapy. Coverage is under the medical benefit; pharmacy coverage is allowed for Glassia.

    • Applies to Aralast NP, Glassia, Prolastin C, and Zemaira (human).
    • Approved dosage and quantity limit: 60 mg/kg by intravenous infusion once weekly.
    Documentation Required

    Initial Authorization Documentation

    For initial authorization, submit chart notes documenting the member’s eligibility, diagnosis, prescriber involvement, smoking status, supportive therapy, and liver-transplant history. Include laboratory documentation supporting severe AATD and the required pulmonary function findings.

    • Member is at least 18 years of age and the medication is prescribed by or in consultation with a pulmonologist.
    • Document clinically evident emphysema due to severe alpha1-antitrypsin deficiency (AATD).

    Clinical Background

    Alpha1-antitrypsin deficiency is a hereditary disorder caused by pathogenic mutations in the SERPINA1 gene. These mutations result in low alpha1-antitrypsin levels, allowing relatively unopposed protease activity that can contribute to lung destruction and an increased risk of emphysema. Alpha1-proteinase inhibitor augmentation therapy is used to restore and maintain protective alpha1-antitrypsin levels and help slow progression of lung damage.

    Definitions

    Alpha-1 antitrypsin deficiency (AATD)
    CausePathogenic mutations in the SERPINA1 gene
    ResultLow levels of alpha1-antitrypsin
    Clinical riskRelatively unopposed protease activity can cause lung destruction and emphysema
    Other possible involvementThe liver and, less commonly, the skin may also be affected
    Alpha1-proteinase inhibitor
    Therapy typeIntravenous augmentation therapy
    SourceDerived from pooled human plasma donors

    Initial Authorization

    Initial Authorization

    Initial therapy is covered only when all eligibility, clinical, laboratory, pulmonary, and exclusion criteria are met.

    Initial authorization

    • Eligibility and clinical requirements

      • Member is at least 18 years of age.
      • Medication is prescribed by or in consultation with a pulmonologist.
      • Member has a diagnosis of clinically evident emphysema due to severe alpha1-antitrypsin deficiency.
      • Member is a never-smoker or has been a non-smoker for at least 3 months.

    Reauthorization

    Reauthorization

    Reauthorization requires continued smoking abstinence and at least one treatment-response or disease-monitoring finding.

    • Continued smoking abstinence

      • Member continues to abstain from smoking.
    • Treatment response or disease monitoring

      • AAT level is at or above the protective threshold.AAT ≥11 micromol/L
      • Spirometry results demonstrate a slowed rate of FEV1 decline.

    Products and Quantity Limits

    Quantity limits
    Covered productsAralast NP, Glassia, Prolastin C, and Zemaira (human)
    Dose60 mg/kg
    FrequencyOnce weekly
    RouteIntravenous infusion
    Policy Summary
    PayerCareSource Georgia Medicaid
    PolicyAlpha1-proteinase inhibitor augmentation therapy for severe alpha1-antitrypsin deficiency
    Policy CodePolicy GA-MED-P-366579
    Change TypeClinical criteria and coverage update
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for alpha1-proteinase inhibitor therapy; the benefit is medical, with pharmacy coverage allowed for Glassia.
    SourceLink
    On This Page
    Coverage CriteriaClinical ThresholdsAuthorization and DocumentationClinical BackgroundDefinitionsInitial AuthorizationReauthorizationProducts and Quantity Limits
    Protective alpha1-antitrypsin level for reauthorization
    Protective threshold11 micromol/L or above
    UseMay satisfy the treatment-response criterion for reauthorization
    Additional requirementThe member must continue to abstain from smoking for reauthorization
  1. Document that the member is a never-smoker or has been a non-smoker for at least 3 months.
  2. Document compliance with at least one prescribed supportive therapy, such as bronchodilators, pulmonary rehabilitation, or oxygen.
  3. Chart notes must include a pre-treatment AAT serum level less than 11 micromol/L (or equivalent), a high-risk genotype such as Pi*ZZ, Pi*ZNull, or Pi*NullNull, and a pre-treatment FEV1 65% predicted or less.
  4. Document that the member has not had a liver transplant.
  5. When all criteria are met, initial authorization is approved for 6 months.
  6. Documentation Required

    Reauthorization Documentation

    For reauthorization, submit documentation that the member continues to abstain from smoking and that treatment response or disease monitoring supports continuation.

    • Document continued smoking abstinence.
    • Provide at least one of the following: AAT level at or above the protective threshold of 11 micromol/L; slowed rate of FEV1 decline demonstrated by spirometry; or CT densitometry demonstrating slowed progression of anatomic lung disease.
    • When all reauthorization requirements are met, coverage is approved for an additional 12 months.
    Denial Risk

    Initial Authorization Denial Conditions

    Initial authorization will be denied when any required criterion is not met or required documentation is not submitted.

    • Member is under 18 years of age.
    • Medication is not prescribed by or in consultation with a pulmonologist.
    • No clinically evident emphysema due to severe AATD is documented.
    • Member is a current smoker or has not been a non-smoker for at least 3 months.
    • Member is not compliant with prescribed supportive therapy.
    • Required laboratory findings are absent or do not show an AAT serum level less than 11 micromol/L, a high-risk genotype, and a pre-treatment FEV1 65% predicted or less.
    • Member has had a liver transplant.
    Denial Risk

    Reauthorization Denial Conditions

    Continuation authorization will be denied when the member does not continue to abstain from smoking or when treatment response or disease monitoring is not demonstrated.

    • Continued smoking abstinence is not documented.
    • No AAT level at or above 11 micromol/L is documented.
    • Spirometry does not demonstrate a slowed rate of FEV1 decline.
    • CT densitometry does not demonstrate slowed progression of anatomic lung disease.
    • At least one qualifying response or monitoring result is not provided.
    Note

    Unlisted Indication

    Alpha1-proteinase inhibitor therapy is not medically necessary for conditions or indications not listed in this policy. For any other indication, refer to the applicable OffLabel policy.

    • Unlisted indications are subject to the OffLabel policy.
    • Coverage is not medically necessary when the indication is not listed in this document.
    PurposeRestores and maintains alpha1-antitrypsin to protective levels
    Mechanism and goalInhibits proteases such as neutrophil elastase to slow progression of lung damage and emphysema
    Member is in compliance with at least one prescribed supportive therapy, such as bronchodilators, pulmonary rehabilitation, or oxygen.
  7. Member has not had a liver transplant.
  8. Required laboratory and pulmonary findings

    • Pretreatment alpha1-antitrypsin serum level is less than 11 micromol/L or equivalent.AAT <11 micromol/L
    • High-risk genotype is documented, such as Pi*ZZ, Pi*ZNull, or Pi*NullNull.
    • Pretreatment FEV1 is 65% predicted or less.FEV1 ≤65% predicted
  9. CT densitometry demonstrates slowed progression of anatomic lung disease.